Compare DENTSPLY SIRONA Inc (XRAY) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DENTSPLY SIRONA Inc vs Xylem, Inc. — how do they compare? DENTSPLY SIRONA Inc trades at $10.7 (market cap $2.14B), while Xylem, Inc. trades at $107.96 (market cap $25.13B). The key difference: Xylem, Inc. is far larger — about 11.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| XRAY | XYL | |
|---|---|---|
Market Cap | $2.14B | $25.13B |
Sector | Health | Industrials |
52-Week High | $14.68 | $152.95 |
52-Week Low | $9.64 | $105.69 |
Enterprise Value | $4.21B | $26.91B |
Dividend Yield | 5.04% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing pressure from declining revenues and negative profitability. The stock shows a bearish technical signal, with key support at $10. Recent Q2 2026 earnings beat estimates but sales fell 4.1%, highlighting persistent challenges in dental markets. Cash flow improved in 2025, yet net losses and high debt levels remain concerns.
The outlook is cautious; while analyst consensus suggests modest upside to a $12.50 target, weak margins, falling sales, and potential fiduciary scrutiny pose significant risks. Recovery depends on successful execution of the company's turnaround plan amid competitive and macroeconomic headwinds.
Xylem (XYL) trades at $108.81, up 2.95% in the last session, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.46 exceeding expectations. Revenue growth has been steady, rising from $5.5B in 2022 to $9.0B in 2025, while net income margins improved to 10.59%. Recent corporate actions include a dividend declaration and strategic acquisitions to bolster its industrial presence.
The outlook for XYL is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Upside potential is supported by a consensus price target of $152.29, implying significant appreciation. Risks include execution of recent acquisitions and macroeconomic pressures on industrial demand. The stock presents a compelling opportunity for long-term investors focused on water infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
